DXR

Basilea provides portfolio status update

Retrieved on: 
Vendredi, janvier 5, 2024
European Commission, Partnership, Yeast, ABSSSI, Fungus, FDA, Antifungal, PDUFA, DXR, WHO, European, Staphylococcus aureus, Genetically modified bacteria, NDA, Bronchopneumonia, SAB, Civil service commission, USD, Infection, Candida auris, Fungal infection, World Health Organization, Biofilm, Patient, Staphylococcus, CABP, Pharmaceutical industry

By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.

Key Points: 
  • By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.
  • In August, Basilea submitted a similar application for a pediatric label extension of Cresemba in the European Union and anticipates a decision by the European Commission around mid-2024.
  • Basilea expects to enter into a commercialization partnership agreement for ceftobiprole in the US prior to the FDA decision.
  • For fosmanogepix, Basilea anticipates to start a phase 3 study in invasive yeast infections mid-2024 and a phase 3 study in invasive mold infections, by year-end 2024.

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

Retrieved on: 
Jeudi, mars 23, 2023
Pressure, Diuretic, Heart failure, HF, DXR, BVA, Patient, Mortality, Therapy, Conference, NYSE, Pharmaceutical industry

Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. The conference was held March 20-22, 2023 in Boston, Mass.

Key Points: 
  • Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure.
  • The study, titled “Persistent Pressure-Volume Dissociation During CardioMEMS Monitoring,” compared volume and pressure in heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxor’s blood volume analysis (BVA) diagnostic.
  • Veraprapas Kittipibul M.D., lead investigator of the study concluded, “Less than half of patients had concordant pressure-volume changes during CardioMEMS monitoring.
  • This study confirms the significant body of evidence that pressure measurements are not adequate substitutes for direct measurements of circulating volume and that both metrics add valuable but different clinical data for the management of patients.

Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients

Retrieved on: 
Jeudi, mars 23, 2023
RCT, DXR, Therapy, BVA, Heart failure, Patient, Standard of care, NYSE, Conference, Pharmaceutical industry

Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 patients. Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass.

Key Points: 
  • Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 patients.
  • Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass.
  • Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care.
  • “Until we measure blood volume, we really don't know if patients have a normal blood volume or not.

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Retrieved on: 
Mercredi, janvier 11, 2023
Cryptococcosis, SAB, CLK, TARGET, Merck, New Drug Application, Staphylococcus aureus, FGFR, Regulation of tobacco by the U.S. Food and Drug Administration, Aspergillosis, CHF, PARG, DXR, Mucormycosis, Marketing, BARDA, Growth, Food, Subclinical infection, Patient, Research, ABSSSI, Glioblastoma, Gram-negative bacteria, Ceftobiprole, LR, Pharmaceutical industry, Vaccine, Isavuconazonium, EU

CHF 122 million, exceeding guidance by more than 17%

Key Points: 
  • CHF 122 million, exceeding guidance by more than 17%
    Ad hoc announcement pursuant to Art.
  • Revenue contributions from the antifungal Cresemba and the antibiotic Zevtera are expected to amount to approximately CHF 122 million (full-year 2022 guidance: CHF 98 million – 104 million).
  • David Veitch, Chief Executive Officer, commented: “We achieved significant milestones in 2022 and will continue to focus on delivering on our strategy to drive value creation going forwards.
  • By November 2022, Basilea had entered into three separate transactions with innovative oncology companies.

New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care

Retrieved on: 
Lundi, octobre 3, 2022
ASM, U.S. Department of Defense Strategy for Operating in Cyberspace, BVA, Doctor of Philosophy, Medicare, Mortality, SEC, Private Securities Litigation Reform Act, NIH, Blood volume, FDA, Center, Death, COVID-19, CMS, Centers for Medicare & Medicaid Services, DXR, NYSE, Patient, Heart failure, Forward-looking statement, Heart Failure Society of America, Risk, Critical care, GLOBE, Pharmaceutical industry, Risk management

Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC.

Key Points: 
  • Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 which brought together the worlds leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC.
  • Jonathan Feldschuh, Chief Scientific Officer stated, This study shows the substantial benefit of BVA-guided care for Medicare patients with heart failure.
  • The study also showed a 56% lower rate of 30-day rehospitalization which points to a strong economic benefit for payers.
  • Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.

New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures

Retrieved on: 
Lundi, octobre 3, 2022
ASM, U.S. Department of Defense Strategy for Operating in Cyberspace, BVA, Congestion, Mortality, SEC, Health, Private Securities Litigation Reform Act, Man, Physiology, NIH, Blood volume, FDA, Patient, COVID-19, Pressure, Heart failure, DXR, NYSE, HF, Diuretic, Forward-looking statement, Heart Failure Society of America, Risk, Critical care, Woman, GLOBE, Medical device, Pharmaceutical industry

Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC.

Key Points: 
  • Studies from Duke Heart utilizing the Daxor BVA-100 diagnostic in patients with an implantable pulmonary pressure monitor highlighted that the commonly used pressure metric does not correlate with actual blood volume.
  • The clinical implications are significant, as managing patients for cardiovascular congestion based on pressure measures alone might not be sufficient.
  • Highlights from the two studies included:
    Pressure-Volume Profiles in Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction: This study compared the differences in pressure-volume profiles between two common HF phenotypes.
  • Despite similar baseline characteristics, men had higher absolute total blood volume and greater total blood volume percent deviation compared to women with similar pressures.

Dynamic Funds announces proposed Fund and ETF changes

Retrieved on: 
Vendredi, septembre 16, 2022
Series, Legislation, Intention, Management, DXR, TSX, ETF, Financial adviser, Online gambling

TORONTO, Sept. 16, 2022 /CNW/ - Dynamic Funds announces its intention to seek unitholder approval to amend the investment objectives of Dynamic Retirement Income+ Fund and Dynamic Active Retirement Income+ ETF (TSX: DXR) (together, the Funds), which if approved, would convert each of them to a conventional fund for purposes of applicable securities legislation.

Key Points: 
  • TORONTO, Sept. 16, 2022 /CNW/ - Dynamic Funds announces its intention to seek unitholder approval to amend the investment objectives of Dynamic Retirement Income+ Fund and Dynamic Active Retirement Income+ ETF (TSX: DXR) (together, the Funds), which if approved, would convert each of them to a conventional fund for purposes of applicable securities legislation.
  • The Manager believes that the proposed changes will benefit unitholders by providing a structure from which the portfolio manager can most effectively meet the investment objectives of the Funds.
  • The proposed changes to the investment objectives of the Funds will be voted on at special meetings of unitholders to be held on October 18, 2022, in Toronto, Ontario.
  • If the proposal is approved and implemented, the management fee of both Dynamic Retirement Income+ Fund (for all series except Series O) and Dynamic Active Retirement Income+ ETF will be reduced by 5 basis points, effective on or about October 28, 2022.

Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022

Retrieved on: 
Jeudi, août 25, 2022
Length of stay, Mortality, Security (finance), COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, BVA, Department of Defence, CEO, Call, NYSE, Research, United States Department of Defense, Critical care, Heart failure, Blood volume, Department, DXR, Forward-looking statement, SEC, NIH, Investment, U.S. Securities and Exchange Commission, GLOBE, Company, FDA, Form, Risk, Private Securities Litigation Reform Act, Growth, ICU, Patient, Risk management, Pharmaceutical industry, Conference

Oak Ridge, TN, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2022.

Key Points: 
  • Additionally, revenue growth was driven by the United States Department of Defense (DoD) orders as well as third-party companies contracting with Daxor to conduct blood volume analysis on their products.
  • The Company also reported its successful execution of a Department of Defense contract to build a next-generation portable rapid blood volume analyzer for both military and civilian use.
  • Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Basilea to become a leading anti-infectives company backed by strong financial results 2021

Retrieved on: 
Mardi, février 15, 2022
Cryptococcosis, New Drug Application, Patient, Aspergillosis, Webcast, CET, SIX Swiss Exchange, Food, Cancer, FGFR, Board of directors, CHF, Infection, Glioma, PFS, National Medical Products Administration, Center, DCR, Center for Drug Evaluation and Research, IND, FGFR2, NMPA, Adult, Mucormycosis, Acinetobacter baumannii, Isavuconazonium, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EB1, Progression-free survival, Glioblastoma, SAB, PLK1, ICCA, DXR, TTK, Investigational New Drug, FDA, Population, Mycosis, Pfizer, Board, Communication, USD, Partnership, NDA, Research, MCI, ORR, Plasma protein binding, Pharmaceutical industry

The excellent commercial performance triggered several milestone payments from our partners with a total of approximately CHF 35 million in 2021.

Key Points: 
  • The excellent commercial performance triggered several milestone payments from our partners with a total of approximately CHF 35 million in 2021.
  • The first approval in December 2021 triggered a USD 10 million milestone payment to Basilea.
  • Basilea Pharmaceutica Ltd. will host a conference call and webcast today, Tuesday, February15, 2022, at 4 p.m. (CET), to discuss the Companys financial and operating results and to provide an outlook.
  • Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland.

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

Retrieved on: 
Vendredi, janvier 21, 2022
Forward-looking statement, Patient, Suffolk University, Regulatory affairs, Center, Private Securities Litigation Reform Act, Office of Inspector General, U.S. Department of Health and Human Services, SEC, MPA, Board of directors, Pfizer, NYSE, Policy, CEO, Blood volume, Federal Register, GLOBE, Human services, Roche, Master of Public Administration, Henry Ford Health System, U.S. Department of Defense Strategy for Operating in Cyberspace, JD, Heart failure, BVA, Medicare, Centers for Medicare & Medicaid Services, Risk, Communication, State government, FDA, Management, DXR, Board, Critical care, Pharmaceutical industry, Director, Omnicom Group

Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD, MPA to its Board of Directors, effective January 18, 2022.

Key Points: 
  • Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD, MPA to its Board of Directors, effective January 18, 2022.
  • I am honored to join Daxors Board of Directors and look forward to helping Daxor succeed in the coming year and beyond, said Caleb DesRosiers.
  • I am excited to join such an esteemed group of Directors and look forward to supporting the entire Daxor team.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.